Edition:
India

Genmab A/S (GEN.CO)

GEN.CO on Copenhagen Stock Exchange

951.20DKK
18 Jun 2018
Change (% chg)

kr.-9.20 (-0.96%)
Prev Close
kr.960.40
Open
kr.958.00
Day's High
kr.970.60
Day's Low
kr.951.20
Volume
158,759
Avg. Vol
265,955
52-wk High
kr.1,486.00
52-wk Low
kr.880.80

Select another date:

Mon, May 28 2018

Danish biotech Genmab hit by ending of trial using key cancer drug

COPENHAGEN Shares in Danish biotech Genmab fell by as much as 25 percent on Monday after its partner Johnson & Johnson decided to ditch a study using its blockbuster cancer drug.

BRIEF-Genmab: Q1 Net Sales Of Darzalex At $432 Mln

* REG-GENMAB ANNOUNCES NET SALES OF DARZALEX® (DARATUMUMAB) FOR FIRST QUARTER OF 2018

Biotech group Genmab aims to own bigger share of new drug pipeline

COPENHAGEN, April 10 Genmab plans to own a bigger share of drugs in its early-stage pipeline as Europe's biggest biotechnology company prepares to reduce its reliance on a blockbuster cancer drug, marketed by partner Johnson & Johnson.

BRIEF-Genmab ‍2017 Operating Profit Beats Expectations

* ‍PROJECTED REVENUE FOR 2018 CONSISTS PRIMARILY OF DARZALEX ROYALTIES OF APPROXIMATELY DKK 1,750 MLN THAT ARE BASED ON AN ESTIMATED USD 2.0 - 2.3 BLN OF DARZALEX NET SALES IN 2018​

BRIEF-Genmab 2017 Net Sales Of DARZALEX At $1.24 Billion

* ANNOUNCES 2017 NET SALES FIGURES FOR DARZALEX® (DARATUMUMAB)

BRIEF-Genmab Gets USD 50 Mln From Novartis For Lost Potential Milestones And Royalties​

* ANNOUNCES NOVARTIS’ INTENTION TO TRANSITION ARZERRA® (OFATUMUMAB) FROM COMMERCIAL AVAILABILITY TO LIMITED AVAILABILITY VIA COMPASSIONATE USE PROGRAMS FOR THE TREATMENT OF CLL IN NON-US MARKETS

BRIEF-U.S. FDA Grants Priority Review For Daratumumab In Front Line Multiple Myeloma

* U.S. FDA GRANTS PRIORITY REVIEW FOR DARATUMUMAB IN FRONT LINE MULTIPLE MYELOMA

BRIEF-Gemnab Says Artisan Partners Increased Indirect Ownership In Co To 5.04 Pct Of Share Capital and Voting Rights

* GENMAB - ‍ARTISAN PARTNERS INCREASED THEIR INDIRECT OWNERSHIP IN CO TO 3,081,731 SHARES, AMOUNTING TO 5.04% OF SHARE CAPITAL, VOTING RIGHTS IN CO

Select another date: